This has led to its approval by the Food and Drug Administration for the treatment of moderate to severe IBD in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with tumor necrotic factor (TNF) antagonists, or who failed or were intolerant to treatment with one or more tumor necrotic factor (TNF) blockers [18]. The gene discussed is TNF; the disease is inflammatory bowel disease.